Cancer Cachexia: Cause, Diagnosis, and Treatment
- PMID: 28825869
- DOI: 10.1177/0884533617722986
Cancer Cachexia: Cause, Diagnosis, and Treatment
Abstract
Patients with cancer frequently experience unintended weight loss due to gastrointestinal (GI) dysfunction caused by the malignancy or treatment of the malignancy. However, others may present with weight loss related to other symptoms not clearly associated with identifiable GI dysfunction such as anorexia and early satiety. Cancer cachexia (CC) is a multifactorial syndrome that is generally characterized by ongoing loss of skeletal muscle mass with or without fat loss, often accompanied by anorexia, weakness, and fatigue. CC is associated with poor tolerance of antitumor treatments, reduced quality of life (QOL), and negative impact on survival. Symptoms associated with CC are thought to be caused in part by tumor-induced changes in host metabolism that result in systemic inflammation and abnormal neurohormonal responses. Unfortunately, there is no single standard treatment for CC. Nutrition consequences of oncologic treatments should be identified early with nutrition screening and assessment. Pharmacologic agents directed at improving appetite and countering metabolic abnormalities that cause inefficient nutrient utilization are currently the foundation for treating CC. Multiple agents have been investigated for their effects on weight, muscle wasting, and QOL. However, few are commercially available for use. Considerations for choosing the most appropriate treatment include effect on appetite, weight, QOL, risk of adverse effects, and cost and availability of the agent.
Keywords: anabolic agents; anti-inflammatory agents; appetite stimulants; cachexia; cancer; corticosteroids; malnutrition; progestational agents; weight loss.
Similar articles
-
Treatment of unintentional weight loss in patients with cancer.Nutr Clin Pract. 2005 Aug;20(4):400-10. doi: 10.1177/0115426505020004400. Nutr Clin Pract. 2005. PMID: 16207680 Review.
-
Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.Lancet Oncol. 2015 Jan;16(1):108-16. doi: 10.1016/S1470-2045(14)71154-4. Epub 2014 Dec 16. Lancet Oncol. 2015. PMID: 25524795
-
Treatment of cachexia: an overview of recent developments.J Am Med Dir Assoc. 2014 Dec;15(12):866-72. doi: 10.1016/j.jamda.2014.09.007. Epub 2014 Nov 20. J Am Med Dir Assoc. 2014. PMID: 25455531 Review.
-
Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia.Nutrition. 2001 Jan;17(1 Suppl):S1-20. doi: 10.1016/s0899-9007(01)80001-0. Nutrition. 2001. PMID: 11428126 Review. No abstract available.
-
[Feeding-related disorders in medicine, with special reference to cancer anorexia-cachexia syndrome].Rinsho Byori. 2006 Oct;54(10):1044-51. Rinsho Byori. 2006. PMID: 17133993 Review. Japanese.
Cited by
-
A Review of Olanzapine in the Treatment of Cancer Anorexia-Cachexia Syndrome.Pharmacy (Basel). 2024 Feb 17;12(1):34. doi: 10.3390/pharmacy12010034. Pharmacy (Basel). 2024. PMID: 38392941 Free PMC article. Review.
-
Traditional herbal medicine for anorexia in patients with cancer: a systematic review and meta-analysis of randomized controlled trials.Front Pharmacol. 2023 Jun 27;14:1203137. doi: 10.3389/fphar.2023.1203137. eCollection 2023. Front Pharmacol. 2023. PMID: 37441530 Free PMC article.
-
Development of skeletal muscle fibrosis in a rodent model of cancer cachexia.Cell Biochem Funct. 2023 Jun;41(4):478-489. doi: 10.1002/cbf.3797. Epub 2023 May 7. Cell Biochem Funct. 2023. PMID: 37150891 Free PMC article.
-
Home Artificial Nutrition and Energy Balance in Cancer Patients: Nutritional and Clinical Outcomes.Nutrients. 2022 Oct 14;14(20):4307. doi: 10.3390/nu14204307. Nutrients. 2022. PMID: 36296990 Free PMC article.
-
Three Pathways of Cancer Cachexia: Inflammation, Changes in Adipose Tissue and Loss of Muscle Mass-The Role of miRNAs.J Pers Med. 2022 Aug 31;12(9):1438. doi: 10.3390/jpm12091438. J Pers Med. 2022. PMID: 36143223 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources